Kornimate/medical-research-clean huggingface dataset:
a pilot study of the treatment of central serous chorioretinopathy with ketoconazole

Conditions: Chronic Central Serous Chorioretinopathy

Summary: the purpose of this study is to determine the effect of an adrenocorticoid antagonist (ketoconazole), 600 mg per day for 4 weeks, in the treatment of patients with central serous chorioretinopathy (csc).

a complete ophthalmic evaluation and tests: autofluorescence and fluorescein angiography, color fundus photography, oct, including liver and adrenal functions and pregnancy test, if applicable will be done on the screening visit. if the patient is eligible, the patient will be started on ketoconazole 600 mg per day by mouth for the following next 6 weeks. the patient will be rechecked at weeks 5-6, 10,14 and 18. during all these visits a complete ophthalmic examination autofluorescence, oct, and color fundus photographs will be done. repeat liver and adrenal function tests will be done at weeks 5-6 and 10 visits. on the exit visit, all the ophthalmic tests and procedures on the baseline visit will be done. adverse events, and concomitant medications and treatments will be reported on all visits.

Eligibility criteria:
inclusion criteria: 1. age less than 60 years 2. must have clinical signs of csc with leakage from the level of the rpe during fluorescein angiography and neurosensory detachment documented by optical coherence tomography (oct). 3. be able to return for all study visits for 3 months' duration. 4. be able to provide written informed consent 5. must have sufficiently clear media to allow for adequate fundus photography exclusion criteria: 1. have choroidal neovascularization. 2. have any evidence of clinically significant intraocular inflammation, angioid streaks, presumed ocular histoplasmosis syndrome, or other precursor of choroidal neovascularization. 3. have additional eye disease that compromises the visual acuity of the study eye. 4. are receiving any systemic steroid therapy 5. have any significant medical history 6. have a history of severe hypersensitivity reaction to any of the dyes or the drug used in the study. 7. have any history of ocular conditions that may mimic csc 8. are pregnant
diagnosis of latent tuberculosis(tb) infection in health care workers using tst and whole blood interferon-γ assay

Conditions: Tuberculosis

Summary: the investigators think that the health care workers who contact frequently with active tuberculosis patients have more increased prevalence of ltbi compared with those who don't.


Eligibility criteria:
inclusion criteria: * health care workers exclusion criteria: * active pulmonary tuberculosis * previous tuberculosis history * below 20 years old * history of hypersensitivity about ppd * pregnant

Keywords: latent tuberculosis prevalence of health care workers
ultrasound guided blocks of the iliohypogastric and ilioinguinal nerves in persistent postherniorrhaphy pain patients

Conditions: Pain

Summary: in this controlled study the investigators will examine the analgesic and sensory effects of ultrasound-guided blocks of the iliohypogastric and ilioinguinal nerves with lidocaine in persistent postherniorrhaphy pain patients.


Eligibility criteria:
inclusion criteria: * patients older than 18 years with severe postherniorrhaphy pain (numerical rating scale \[nrs\] \> 6) for more than 6 month exclusion criteria: * known amide local anesthetic drug allergy * recurrent hernia

Keywords: persistent postherniorrhaphy pain
a single dose of compound sb-681323 compared to prednisolone on a protein that is an indicator for rheumatoid arthritis

Conditions: Arthritis, Rheumatoid

Summary: this study is designed to compare a range of doses of sb-681323 with prednisolone, which has known effects on rheumatoid arthritis patients. by comparing the two drugs and their effects on blood proteins that indicate for rheumatoid arthritis, we hope to ascertain information on the most effective dose of sb-681323 to use in future.


Eligibility criteria:
inclusion criteria: * must have a diagnosis of ra according to the revised 1987 criteria of the american college of rheumatology. * must have 3 or more swollen or 3 or more tender/painful joints at screening. * must be on stable weekly methotrexate (2.5mg - 25mg) for at least eight weeks prior to screening. exclusion criteria: * must not be morbidly obese.

Keywords: sb-681323 rheumatoid arthritis crp biomarkers
combined phacoemulsification and diode laser therapy in chronic angle closure glaucoma

Conditions: Angle Closure Glaucoma

Summary: comparing different types of cuclophotocoagulation with cataract extraction to cataract extraction and goniocynechiolysis in cases of chronic angle closure glaucoma

evaluation of the safety of mp-tscpc , cw-tscpc and endoscopic cyclophotocoagulation when combined with phacoemulsification in cases with cacg comparing the efficacy of the combined procedures in control of the iop and the success rate versus lens extraction combined with synechiolysis

Eligibility criteria:
inclusion criteria: * patients between 20 to 70 years chronic angle closure glaucoma exclusion criteria: * patients in acute attack of angle closure. * patients with previous filtering surgery or cycloablative procedure

Keywords: angle closure glaucoma cyclophotocoagulation
efficacy of biofeedback in the treatment of tic disorder

Conditions: Tic Disorders

Summary: to investigate the efficacy of eeg biofeedback and drug therapy in the treatment of tic disorders

this study intends to investigate the efficacy of eeg biofeedback and drug therapy on clinical symptoms, cognitive flexibility and quality of life in chronic tic disorder and tourette syndrome through a randomized controlled study.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria of diagnostic and statistical manual of mental disorders(fifth edition,dsm-5) for chronic tic disorder or tourette syndrome（ts）; * ethnic group is han nationality; * aged 8 \~ 16 years old; * otal iq of wechsler intelligence scale for children ≥ 80 points for subjects; * symptom severity score in yale global severity scale (ygtss), ts patients \> 13, ctd \> 9; * did not receive any drug (including traditional chinese medicine) treatment 4 weeks before enrollment; * obtain written informed consent from children and guardians exclusion criteria: * epilepsy, cardiovascular disease * patients with schizophrenia, mental retardation, autism spectrum disorder, bipolar disorder and major depression who meet the dsm-5 diagnostic criteria; * receiving systematic traditional chinese medicine treatment one month before enrollment or currently; * receiving systematic psychotherapy one month before enrollment or currently; * receive systematic physical therapy one month before enrollment or currently * those who cannot follow the doctor's advice or refuse to cooperate; * those with obvious abnormal laboratory test results (ast or alt ≥ 2 times of the upper limit of normal value; bun ≥ 1.5 times of the upper limit of normal value; cr ≥ 1.2 times of the upper limit of normal value); * prolongation of qtc interval (qtc ≥ 450 ms in men or ≥ 470 ms in women);

Keywords: biofeedback drug therapy clinical efficacy cognitive flexibility
n-phenogenics: neurocognitive-phenome, genome, epigenome and nutriome in childhood leukemia survivors

Conditions: Childhood Leukemia Survivors

Summary: to find possible therapeutic targets to help prevent long-term brain and behavioural side effects in survivors of childhood leukemia that may have been caused by chemotherapy (treatment-related late adverse neuro-cognitive effects: trance). the study hypothesis is that genetic variations of the elements in the folate-related cycles and methotrexate disposition networks are associated with the deficit phenotype (trance) of childhood leukemia survivors.

hypothesis genetic variants of the elements in the folate-related cycles and methotrexate disposition networks are associated with the trance phenotype of childhood leukemia survivors. objectives 1. to identify trance phenotypes of the childhood leukemia survivors. 2. to characterize the folate and vitamin b12 levels of these children 3. to identify dna methylation patterns associated with trance trait in the leukemia survivors 4. to identify snps associated with the trance trait in the leukemia survivors. 5. to identify the "deficit genotype" associated only with the trance leukemia survivors, but not with general population children who show developmental phenotypes similar to trance: trance-unique deficit variant 6. to replicate the association between the trance-unique deficit variants and the trance trait in a population of childhood leukemia survivors. 7. to evaluate the importance of rare genetic variants in the trance trait in the leukemia survivors. study design: a case-control study of leukemia survivors analyses 1. leukemia survivors will be characterized by their status of neurocognitive function, and categorized into the deficit case and the non-deficit control case. 2. they will be also characterized by the following attributes 1. pathway-based genetic variant status (folate and pk-related genes) 2. folate and vitamin b12 status 3. epigenetic markers 3. comparative analyses between neuro-cognitiive deficit phenotype (trance) and control on those parameters

Eligibility criteria:
inclusion criteria: * past diagnosis of acute lymphoblastic leukemia * 8 years : 0 months - 20 years : 11 months old at the time of their study visit * at least 2 years : 0 months from the last treatment for acute lymphoblastic leukemia at the time of their study visit * continuous complete remission and undergone no bone marrow transplantation or cranial radiation therapy * fluent in english (a subject and one parent) for test completion * signed informed consent exclusion criteria: * inability to complete the phenotyping tests * down syndrome diagnosis

Keywords: childhood leukemia survivors acute lymphoblastic leukemia leukemia late effects folate blood folate neurotoxicity methotrexate pharmacogenetics cognitive cognitive late effects n-phenogenics
ultrasound with subharmonic imaging and subharmonic aided pressure estimation (shape) to identify portal hypertension

Conditions: Portal Hypertension

Summary: this clinical trial tests the how well an ultrasound with subharmonic imaging and the subharmonic aided pressure estimation (shape) technique works in identifying portal hypertension (ph). an ultrasound takes pictures of the inside of the body by bouncing sound waves off organs. ph is high blood pressure in the vein that carries blood to the liver from the stomach, small and large intestines, spleen, pancreas, and gallbladder. the complications associated with ph are clear only after severe liver dysfunction or liver cirrhosis develops and are accompanied by relatively high mortality rates (20-70% mortality within 2 years). thus, identifying ph earlier is beneficial. the hepatic venous pressure gradient (hvpg) obtained using an invasive catheterization procedure remains the standard for assessing ph. however, using this invasive procedure to assess ph prevents frequent pressure monitoring. thus, a noninvasive technique to estimate ph is beneficial not only for diagnosis but also for monitoring treatment and disease progression. the shape technique is a noninvasive ultrasound-based imaging technique that can estimate pressure with an ultrasound contrast agent. a noninvasive technique using an ultrasound with subharmonic imaging and the shape technique may work in identifying ph.

primary objectives: i. to evaluate if shape with perflutren lipid microspheres (definity) microbubbles identifies patients with clinically significant ph. ii. to evaluate if addition of subharmonic imaging-based perfusion parameters derived from time intensity curves and shear wave elastography (swe) measurements increase the diagnostic confidence of detecting ph. outline: patients receive definity intravenously (iv) once on study. additionally, patients undergo ultrasound with and without shape technique as well as standard of care liver biopsy on study. after completion of study intervention, patients are followed up for 30 minutes.

Eligibility criteria:
inclusion criteria: * provide signed and dated informed consent form * willing to comply with all study procedures * adult patients (age of 18 years or older) * if a female of child-bearing potential, must have a negative pregnancy test * be scheduled for hvpg measurement exclusion criteria: * patients who are unable to provide consent * females who are pregnant or nursing * patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (peg)
perioperative treatment of parkinsonian patients with parenteral amantadine

Conditions: Parkinson Disease; Perioperative Care

Summary: the purpose of this study is to determine whether administrating of amantadine (a dopamine agonist) to patients suffering from parkinson disease during the perioperative period is safe, and to asses potential benefits of this treatment.


Eligibility criteria:
inclusion criteria: * patient with a diagnosis of parkinson disease refered for surgery at our institution. exclusion criteria: * cardiac and neurosurgical procedures * inability to sign informed consent * allergy to amantadine * congestive heart failure * arrythmia (including bradycardia below 55 bpm) * renal failure (creatinin above 1.5) * if a patient will develop agitation or delirium lasting longer then 8 hours he will not receive the second dose of amantadine.

Keywords: amantadine
organoids from metastases of prostate cancer

Conditions: Prostatic Neoplasm

Summary: the aim of the study is the development of the organoid culture technique from metastases from patients with advanced form of prostate cancer. once the technique is set up, the organoid will serve to test several antitumor molecules.


Eligibility criteria:
inclusion criteria: * patient with metastatic prostate cancer * patient having a biopsy programmed as part of his care. * patient having a biopsy programmed as part of hiscare. * patient with sufficient tumor volume after imaging data review by the radiologist to guarantee a sufficient quantity of material for the diagnosis of biopsy and additional material for the study. * inr \ 50000 / μl exclusion criteria: * patient under age of 18 years. * patient under plavix or effient or ticlid without possibility of suspension for 5 days, low molecular weight heparin without possibility of suspension of the dose before the intervention, or fondaparinux without possibility of suspension, or reopro without possibility of suspension for 24h and aptt \ 50 ml / min or 3h to 5h if crcl \ 50 ml / min or 3 to 5 days if crcl \<50 ml / min before the procedure * patient under desmopressin acetate (ddavp) * patient with hiv or hepatitis c positive or hepatitis b infection, defined by either a detection of the hbs antigen or the presence of anti hbc antibodies without hbs antibody detectable.
an extension study of linifanib (abt-869) in subjects with advanced or metastatic solid tumors

Conditions: Advanced Solid Tumors

Summary: an extension study of linifanib in subjects with advanced or metastatic solid tumors.

this study is designed to evaluate the safety of linifanib in subjects with advanced or metastatic solid tumors.

Eligibility criteria:
inclusion criteria 1. subject has completed a previous study utilizing linifanib (per the criteria in the previous study) or was active and assigned to linifanib when the study was completed and the investigator believes that continued treatment with linifanib is in the best interest of the subject. 2. women of childbearing potential and men must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and up to 90 days following completion of therapy. women of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment and/or post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential: * total abstinence from sexual intercourse (minimum one complete menstrual cycle); * vasectomized partner(s); * hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration; if the subject is currently using a hormonal contraceptive, she should also use a barrier method during this study and for 1 month after study completion; * intrauterine device (iud); * double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or creams); * additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and for 90 days following completion of therapy. 3. is capable of understanding and complying with parameters as outlined in the protocol and able to sign the informed consent, approved by an independent ethic committee (iec)/institutional review board (irb) prior to the initiation of any screening or study-specific procedures. exclusion criteria 1. subject discontinued linifanib administration before completing the prior study (due to disease progression, toxicity, withdrawal of consent, other). 2. subject has any medical condition which in the opinion of the investigator places the subject at an unacceptably high risk for toxicities. 3. subject is a lactating or pregnant female.
characterization of laryngeal contact granulomas: retrospective analysis of symptoms, promotive factors and therapy

Conditions: Laryngeal Contact Granuloma

Summary: retrospective analysis of data from patients with laryngeal contact granulomas in order to identify possible differences and/or similarities between the cases and in order to determine whether and which conclusions can be drawn on disease and therapy.

this is a retrospective analysis of data from patients with laryngeal contact granulomas in order to identify possible differences and/or similarities between the cases and in order to determine whether and which conclusions can be drawn on disease and therapy.

Eligibility criteria:
inclusion criteria: laryngeal contact granuloma in adults with documentation of symptoms, possible causes, therapy and outcome exclusion criteria: incomplete information on the diagnosis laryngeal contact granuloma (symptoms, promotive factors, findings)

Keywords: laryngeal contact granuloma treatment type outcome
patient directed intervention to improve the quality of life for patients with soft tissue sarcoma

Conditions: Soft Tissue Sarcoma

Summary: the primary objective of the study is to compare quality of life (qol) between patients suffering from soft tissue sarcoma, receiving a multidimensional intervention with those receiving standard treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of advanced or metastatic soft tissue sarcoma * treatment with trabectedin in an in-label prescription * age at least 18 years (inclusive) at the first visit * patients with a life expectancy of at least 6 months * the informed consent form must be signed before any study specific tests or procedures are done * confirmation of the subject's health insurance coverage prior to the first visit * ability to understand and follow study-related instructions exclusion criteria: * ecog ps \>2 * estimated life expectancy of less than 6 months * patients with sts not receiving trabectedin * contraindications according to the local smpc of yondelis® * subject is in custody by order of an authority or a court of law * exclusion periods from other studies or simultaneous participation in other clinical studies * previous assignment to treatment during this study * close affiliation with the investigator (e.g. a close relative) or persons working at the study site * subject is an employee of gwt-tud gmbh or pharma mar s.a. * criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the subject's safety

Keywords: palliative treatment trabectedin patient reported outcome
effects of lactobacillus plantarum ps128 on the parkinsonian symptoms in parkinson's disease.

Conditions: Parkinson Disease

Summary: this rct study is designed to examine the extent to which l. plantarum ps128 can improve symptoms in pd patients. l. plantarum ps128 is a psychobiotic that regulates the level of dopamine in specific brain regions. patients with pd will receive ps128 or placebo intervention for 12 weeks. symptoms of pd will be clinically evaluated before and after the treatment, and the results will be compared.

this rct study is designed to examine the extent to which l. plantarum ps128 can improve symptoms in pd patients. l. plantarum ps128 is a psychobiotic that regulates the level of dopamine in specific brain regions. patients with pd will receive ps128 or placebo intervention for 12 weeks. symptoms of pd will be clinically evaluated before and after the treatment, and the results will be compared.

Eligibility criteria:
inclusion criteria: * modified hoehn \&yahr stage, mhy 1-3 * 45-80 years old * at least 9 years education exclusion criteria: * patients on antibiotics within the preceding one month * patients using of other probiotic products (sachet, capsule or tablet) within the preceding two weeks * have undergone surgery of liver, bladder, or gastrointestinal tract * have current or history of inflammatory bowel disease * have history of cancer * known allergy to probiotics * patients with comorbid dementia (mini-mental state examination score ≤ 26) or major depression (the beck depression inventory-ii score ≥ 29) * have received deep brain stimulation * patients receiving artificial enteral or intravenous nutrition * diagnosed before 40 years old * poor control of other chronic diseases * not eligible judged by pi

Keywords: probiotics, parkinson's disease
the effect of non-surgical periodontal therapy on the gingival crevicular fluid levels of prolactin hormone in patients with periodontitis.

Conditions: Periodontitis; Prolactin in GCF

Summary: the present study will be conducted on fifty participants. all participants will receive a full-mouth clinical examination, and the following periodontal parameters will be recorded: plaque index (pi). gingival index (gi), probing depth (pd), and clinical attachment level (cal). all of these measurements will be recorded at six sites at baseline for all participants and 3 months after non-surgical periodontal therapy for the study group. gcf samples will be collected from the buccal aspects of teeth that had the highest signs of inflammation and attachment loss for periodontitis group at baseline and 3 months after non-surgical periodontal therapy. as for controls, the samples will be collected from buccal aspect of upper first molar at baseline. the samples will be assayed for prolactin by using an enzyme linked immunosorbent assay kits (elisa) according to the manufacturer instruction.


Eligibility criteria:
inclusion criteria: * subjects with moderate to severe chronic periodontitis, with probing pocket depth (ppd) ≥ 4-6 mm and clinical attachment level ≥ 4-5 mm, according to the american academy of periodontology.7 * highly motivated and cooperative patients exclusion criteria: * the presence of any systemic disease. * taking medications for the last 3 months before conducting this study. * pregnancy and lactation. * any type of previous periodontal treatment (surgical or non-surgical) in the preceding 6 months. * smoking (former or current).

Keywords: periodontitis prolactin gcf non-surgical periodontal treatment